These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Clinical practice guideline monitoring children and young people with, or at risk of developing autosomal dominant polycystic kidney disease (ADPKD). Dudley J; Winyard P; Marlais M; Cuthell O; Harris T; Chong J; Sayer J; Gale DP; Moore L; Turner K; Burrows S; Sandford R BMC Nephrol; 2019 Apr; 20(1):148. PubMed ID: 31039757 [TBL] [Abstract][Full Text] [Related]
27. Autosomal dominant polycystic kidney disease: a case study. Phillips A Nephrol Nurs J; 2009; 36(1):41-7. PubMed ID: 19271623 [TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease. Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417 [TBL] [Abstract][Full Text] [Related]
29. Clinical Manifestation, Management and Prognosis of Acute Myocardial Infarction in Autosomal Dominant Polycystic Kidney Disease. Yang B; Wang Q; Wang R; Xu T Kidney Blood Press Res; 2018; 43(6):1806-1812. PubMed ID: 30504716 [TBL] [Abstract][Full Text] [Related]
30. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Gansevoort RT; Arici M; Benzing T; Birn H; Capasso G; Covic A; Devuyst O; Drechsler C; Eckardt KU; Emma F; Knebelmann B; Le Meur Y; Massy ZA; Ong AC; Ortiz A; Schaefer F; Torra R; Vanholder R; Więcek A; Zoccali C; Van Biesen W Nephrol Dial Transplant; 2016 Mar; 31(3):337-48. PubMed ID: 26908832 [TBL] [Abstract][Full Text] [Related]
31. Identifying patient-important outcomes in polycystic kidney disease: An international nominal group technique study. Cho Y; Sautenet B; Gutman T; Rangan G; Craig JC; Ong AC; Chapman A; Ahn C; Coolican H; Kao JT; Gansevoort R; Perrone RD; Harris T; Torres V; Pei Y; Kerr PG; Ryan J; Johnson DW; Viecelli AK; Geneste C; Kim H; Kim Y; Oh YK; Teixeira-Pinto A; Logeman C; Howell M; Ju A; Manera KE; Tong A Nephrology (Carlton); 2019 Dec; 24(12):1214-1224. PubMed ID: 30663163 [TBL] [Abstract][Full Text] [Related]
32. Epidemiology of patients in England and Wales with autosomal dominant polycystic kidney disease and end-stage renal failure. Shaw C; Simms RJ; Pitcher D; Sandford R Nephrol Dial Transplant; 2014 Oct; 29(10):1910-8. PubMed ID: 24737444 [TBL] [Abstract][Full Text] [Related]
33. International consensus statement on the diagnosis and management of autosomal dominant polycystic kidney disease in children and young people. Gimpel C; Bergmann C; Bockenhauer D; Breysem L; Cadnapaphornchai MA; Cetiner M; Dudley J; Emma F; Konrad M; Harris T; Harris PC; König J; Liebau MC; Marlais M; Mekahli D; Metcalfe AM; Oh J; Perrone RD; Sinha MD; Titieni A; Torra R; Weber S; Winyard PJD; Schaefer F Nat Rev Nephrol; 2019 Nov; 15(11):713-726. PubMed ID: 31118499 [TBL] [Abstract][Full Text] [Related]
35. The effect of disease severity markers on quality of life in autosomal dominant polycystic kidney disease: a systematic review, meta-analysis and meta-regression. Neijenhuis MK; Kievit W; Perrone RD; Sloan JA; Erwin P; Murad MH; Gevers TJG; Hogan MC; Drenth JPH BMC Nephrol; 2017 May; 18(1):169. PubMed ID: 28545401 [TBL] [Abstract][Full Text] [Related]
36. Complications of autosomal dominant polycystic kidney disease in 50 haemodialysed patients. A case-control study. The U.C.L. Collaborative Group. Christophe JL; van Ypersele de Strihou C; Pirson Y Nephrol Dial Transplant; 1996 Jul; 11(7):1271-6. PubMed ID: 8672022 [TBL] [Abstract][Full Text] [Related]
37. [Two cases of autosomal dominant polycystic kidney disease treated with hemodialysis associated with polycystic liver complications related to the cause of death]. Saima S; Suzuki Y; Yoshimoto K; Nakamura Y; Munakata A Nihon Jinzo Gakkai Shi; 1996 Jun; 38(6):278-84. PubMed ID: 8752971 [TBL] [Abstract][Full Text] [Related]
38. [Quality of life in patients with autosomal dominant polycystic kidney disease]. Lecardeur L; Joly D Nephrol Ther; 2017 Dec; 13(7):505-510. PubMed ID: 28606406 [TBL] [Abstract][Full Text] [Related]
39. The BC ADPKD Network: A Comprehensive Provincial Approach to Support Specialized and Locally Delivered Multidisciplinary ADPKD Care. Bevilacqua M; Gradin S; Williams J; Romann A; Lo C; Djurdjev O; Levin A Can J Kidney Health Dis; 2021; 8():20543581211035218. PubMed ID: 34377502 [TBL] [Abstract][Full Text] [Related]
40. Spanish guidelines for the management of autosomal dominant polycystic kidney disease. Ars E; Bernis C; Fraga G; Martínez V; Martins J; Ortiz A; Rodríguez-Pérez JC; Sans L; Torra R; Nephrol Dial Transplant; 2014 Sep; 29 Suppl 4():iv95-105. PubMed ID: 25165191 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]